About

Fred Turner is a highly accomplished CEO with over 9 years of relevant experience in the biotechnology and healthcare industries. Currently serving as the Chief Executive Officer at Curative, he is leading the company's mission to end COVID-19 by providing over 100,000 tests per day with a 24-hour turnaround time across the United States. In just 8 months, Fred has scaled Curative from nothing to approximately 10% of all US testing. Prior to joining Curative, Fred served as the CEO of Shield Bio, where he played a crucial role in ensuring that antibiotic resistance does not become more deadly than cancer. He has also served as the Chief Executive Officer of TL Biolabs Corp, where he led the development of genomic testing for the dairy industry to determine the characteristics of animals from birth using high-throughput genomics testing technologies. Fred's educational background is impressive, having completed a Master of Biochemistry from the University of Oxford in 2016. He also completed a program at Y Combinator in 2016 and attended The Crossley Heath School. Fred's expertise in the biotechnology and healthcare industries is complemented by his knowledge of technology. He is proficient in a variety of tech stacks, including testing. Overall, Fred Turner is a visionary leader with a proven track record of success in the biotechnology and healthcare industries. His leadership at Curative is playing a crucial role in the fight against COVID-19, and he is poised to continue making a significant impact in the healthcare industry in the years to come.